Clinical trials: Carcinoma of the Head and Neck
Colorectal Cancer, Head and Neck Cancer
Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
The purpose of the study is to determine the safety, tolerability and maximum tolerated dose of Urelumab in combination with Cetuximab in patients with Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell…
- Trial name
- NCT02110082
- Testing
- Urelumab, Cetuximab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- Bristol-Myers Squibb
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00732745
- Testing
- docetaxel, oxaliplatin, vandetanib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Head and Neck Cancer
A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's
The present study is a phase II/III prospective randomized trial designed to determine whether eliminating of post operative radiotherapy to regional lymphatics in pN0-N1oral cavity is associated with similar treatment outcomes.
- Trial name
- Eliminate (NCT07528495)
- Testing
- IMRT - adjuvant concurrent CRT/ RT, ommission of IMRT - adjuvant concurrent CRT/ RT for regional lymphatics, Cisplatin
- Where
- India
- Volunteers
- 396 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences
Advanced Solid Tumors
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
To better understand the safety and tolerability of ALKS 4230 in humans
- Trial name
- NCT02799095
- Testing
- ALKS 4230, ALKS 4230 + pembrolizumab
- Where
- 31 sites in United States, Australia and 5 more
- Volunteers
- 243 people
- Sponsor
- Mural Oncology, Inc
Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
Head and Neck Squamous Cell Carcinoma (HNSCC) is the most common malignant tumor of the head and neck, accounting for 90% of head and neck malignancies, and 16% to 40% of systemic malignancies.
- Trial name
- NCT04947241
- Testing
- PD-1 inhibitor+ Gemcitabine + Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial
- Trial name
- NCT05544929
- Testing
- KFA115, pembrolizumab
- Where
- 18 sites in United States, Canada and 10 more
- Volunteers
- 126 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
Head and Neck Neoplasms, Hearing Disorder
Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation
Background: Cisplatin is a chemotherapy drug. It is used to treat head and neck squamous cell carcinoma (HNSCC) and other cancers. It can cause hearing loss for some people.
- Conditions
- Head and Neck Neoplasms, Hearing Disorder, Hyperlipidemia
- Trial name
- NCT03225157
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Stage I Oral Cavity Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma
Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
This randomized phase II clinical trial studies how well photodynamic therapy with HPPH works compared to standard of care surgery in treating patients with oral cavity cancer.
- Trial name
- NCT03090412
- Testing
- HPPH, Laboratory Biomarker Analysis, Photodynamic Therapy
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Carcinoma
Effects of Human Papillomavirus Diagnosis on Relationships of Patients With Head and Neck Cancer
This trial studies the effects of human papillomavirus diagnosis on the relationships of patients with head and neck cancer. Determining the effects of human papillomavirus diagnosis on relationships may determine whether human…
- Trial name
- NCT04666428
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Jefferson University
Head and Neck Cancer
Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI
The goal of this clinical research study is to learn if ferumoxytol, when given at the time of a magnetic resonance imaging (MRI), can help researchers learn more about the spread of certain kinds of cancers.
- Trial name
- NCT01895829
- Testing
- Magnetic Resonance Imaging (MRI), Ferumoxytol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Squamous Cell Carcinoma of the Head and Neck
Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib.
A single-arm, single-center clinical trial evaluating efficacy (Phase #)
- Trial name
- NCT07550972
- Testing
- A single-arm, single-center clinical trial evaluating efficacy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Provincial People's Hospital
Cancer, Thyroid Cancer
Pharmaceutical Management in Targeted Radioligand Therapy
Targeted Radionuclide Therapy (TRT) is a treatment modality used in nuclear medicine to target cancer cells while preserving surrounding healthy tissues.
- Conditions
- Cancer, Thyroid Cancer, Metastatic Prostate Cancer, Neuroendocrine Tumor Carcinoid
- Trial name
- PharmTRT (NCT07389512)
- Where
- 3 sites in France
- Volunteers
- 600 people
- Sponsor
- Hospices Civils de Lyon
Laryngeal Carcinoma
The Relationship Between The Differential Expression Of FosB Protein In Laryngeal Cancer Tissues And Clinical Prognosis
To determine whether there is statisstical difference in FosB (FBJ murine osteosarcoma viral oncogene homolog B) protein expression between laryngeal cancer tissue and adjacent tissue through immunohistochemistry methods.
- Trial name
- NCT06836765
- Testing
- the expression negative in laryngeal cancer tissue, the expression positive in laryngeal cancer tissue
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yang ji
Cancer of Head and Neck
Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)
The purpose of this study is to evaluate the response of the tumor to the treatment regimen that will be used in this study. This study will also test the safety of cetuximab (C225), given with chemotherapy and radiation therapy.
- Trial name
- NCT00343083
- Testing
- Erbitux, Paclitaxel & Carboplatin, Radiation
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Maryland, Baltimore
Head and Neck Cancer
Docetaxel and S-1 Followed By Radiation Therapy and Low-Dose Cisplatin in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, S-1, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00625937
- Testing
- cisplatin, docetaxel, tegafur-gimeracil-oteracil potassium
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Yonsei University
Head and Neck Squamous Cell Carcinoma
TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin and radiation versus cisplatin and radiation.
- Trial name
- TRACE (NCT00174837)
- Testing
- Tirapazamine, Cisplatin
- Where
- 17 sites in United States, Argentina and 15 more
- Volunteers
- 317 people
- Sponsor
- Sanofi
Head and Neck Squamous Cell Carcinoma
Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC
This study evaluates the efficacy of the new docetaxel-cisplatin-cetuximab regimen (TPEx) versus the standard platinum-5FU-cetuximab EXTREME regimen as a first-line treatment in recurrent and/or metastatic HNSCC.
- Trial name
- TPExtreme (NCT02268695)
- Testing
- Cisplatin, 5-Fluorouracile, Docetaxel
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 541 people
- Sponsor
- Groupe Oncologie Radiotherapie Tete et Cou
Advanced Solid Tumor, Metastatic Solid Tumor
A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors
This study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Colorectal Cancer, Lung Cancer
- Trial name
- NCT04801095
- Testing
- WM-S1-030
- Where
- 6 sites in Australia, South Korea
- Volunteers
- 100 people
- Sponsor
- Wellmarker Bio
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer
The purpose of this study is to explore the use of a treatment called interstitial brachytherapy for patients who have a high risk resectable (able to be treated with surgery) recurrent head and neck cancer.
- Trial name
- NCT02794675
- Testing
- Cesium 131
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.